Abstract
The aim of the present study is to investigate the clinical utility of advanced imaging sequences for DBS targeting in ET. Specifically, we demonstrate that a visual marker that is appreciable on fast gray matter acquisition T1 inversion recovery (FGATIR) sequences (1) can be visualized reliably and reproducibly, (2) can predict symptom improvement in a clinical cohort, and (3) may serve as a surrogate marker for a DBS target that yields optimal tremor suppression. The FGATIR sequence was introduced as part of the clinical imaging acquisition protocol for thalamic DBS at our center with the goal of discerning individual thalamic nuclei. However, during planning procedures, we frequently noticed an oval hypointense marker in close proximity to the identified target at the ventral border of the human motor thalamus. This clinical finding prompted us to retrospectively investigate the neural substrates underlying the marker and probe its predictive utility.
The aim of the present study is to investigate the clinical utility of advanced imaging sequences for DBS targeting in ET. Specifically, we demonstrate that a visual marker that is appreciable on fast gray matter acquisition T1 inversion recovery (FGATIR) sequences (1) can be visualized reliably and reproducibly, (2) can predict symptom improvement in a clinical cohort, and (3) may serve as a surrogate marker for a DBS target that yields optimal tremor suppression. The FGATIR sequence was introduced as part of the clinical imaging acquisition protocol for thalamic DBS at our center with the goal of discerning individual thalamic nuclei. However, during planning procedures, we frequently noticed an oval hypointense marker in close proximity to the identified target at the ventral border of the human motor thalamus. This clinical finding prompted us to retrospectively investigate the neural substrates underlying the marker and probe its predictive utility.
The aim of the present study is to investigate the clinical utility of advanced imaging sequences for DBS targeting in ET. Specifically, we demonstrate that a visual marker that is appreciable on fast gray matter acquisition T1 inversion recovery (FGATIR) sequences (1) can be visualized reliably and reproducibly, (2) can predict symptom improvement in a clinical cohort, and (3) may serve as a surrogate marker for a DBS target that yields optimal tremor suppression. The FGATIR sequence was introduced as part of the clinical imaging acquisition protocol for thalamic DBS at our center with the goal of discerning individual thalamic nuclei. However, during planning procedures, we frequently noticed an oval hypointense marker in close proximity to the identified target at the ventral border of the human motor thalamus. This clinical finding prompted us to retrospectively investigate the neural substrates underlying the marker and probe its predictive utility.
